Navigation Links
ALS TDI and Gladstone Institutes collaborate to discover potential ALS treatments
Date:12/4/2012

CAMBRIDGE, MA and SAN FRANCISCO, CADecember 4, 2012 The ALS Therapy Development Institute (ALS TDI) and the Gladstone Institutes today announced the formation of a research collaboration to speed the discovery of potential treatments for ALS through the preclinical drug development process.

"We are thrilled about the potential this collaboration holds to accelerate ALS therapeutic development," said Steve Perrin, PhD, CEO and Chief Scientific Officer at ALS TDI. "Both our organizations have unique infrastructures, and by linking them this way, we may be able to advance potential treatments faster than before."

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a neurodegenerative disease that leads to paralysisand eventually deathdue to the loss of motor neurons in the spinal cord and brain. About 30,000 people in the United States live with the disease at any given time, and the global population of ALS patients is approximately 400,000. Approximately 5,000 new cases of ALS are diagnosed in the United States each year, and there is no known cause, cure or treatment to halt or reverse the disease. The average patient survives only two to five years following their diagnosis.

Under this new agreement, which starts immediately, Gladstone will evaluate potential pharmaceutical compounds using a human model of ALS. Gladstone generated the model by transforming skin cells from ALS patients into stem cells, known as induced pluripotent stem cells (iPS cells), and then programming them into neurons. The technique builds on a discovery for which Shinya Yamanaka, MD, PhD, a Gladstone senior investigator, won the 2012 Nobel Prize in Physiology or Medicine.

This particular iPS-based ALS model includes a gene mutation that produces TDP-43, a protein commonly found in most forms of ALS. Promising drug compounds that pass the initial evaluation process at Gladstone will be fast-tracked for pre-clinical testing at ALS TDI, which will assess the compounds for activity and efficacy in various mouse models of human neurodegeneration.

"We hope our human model of ALS will help us to move quickly and effectively to identify promising therapeutic candidates for ALS," said Gladstone Senior Investigator Steve Finkbeiner, MD, PhD, who is also a professor of neurology and physiology at the University of California, San Francisco, with which Gladstone is affiliated. "The strong evidence that abnormal TDP-43 protein is involved in the development of ALS, coupled with models that may replicate ALS more faithfully than other tools, may speed development of therapies for the thousands of individuals diagnosed with this devastating disease."


'/>"/>
Contact: Diane Schrick
diane.schrick@gladstone.ucsf.edu
415-734-2538
Gladstone Institutes
Source:Eurekalert

Related biology news :

1. Gladstone, Stanford scientists block toxic protein that plays key role in Lou Gehrigs disease
2. Gladstone scientists identify critical process in stem cell development
3. Gladstone scientist Warner C. Greene receives Washington University School of Medicine Alumni Award
4. TGen leads new National Institutes of Health study of brain tumors
5. USDA scientists collaborate with global researchers to advance the mapping of the barley genome
6. Astellas and DNDi to collaborate on new drug discovery research for the treatment of NTDs
7. BGI and Aspera collaborate on high-speed data exchange to advance genome research
8. HUNT Biosciences and SomaLogic collaborate to validate protein biomarkers of cardiovascular risk
9. American University biologist discovers new crab species
10. Hearty organisms discovered in bitter-cold Antarctic brine
11. Microbial missing link discovered after man impales hand on tree branch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/7/2017)... , March 7, 2017   HireVue , the ... global companies identify the best talent, faster, today announced ... Sales Officer (CSO) and Diana Kucer as ... out a seasoned executive team poised to drive continued growth ... on a year of record bookings in 2017. ...
(Date:3/2/2017)... 2, 2017 Australian stem cell and regenerative ... has signed an agreement with the Monash Lung Biology ... Discovery Institute and Department of Pharmacology at Monash University, ... preclinical study to support the use of Cymerus™ mesenchymal ... Asthma is a chronic, long term lung ...
(Date:2/27/2017)... WASHINGTON , Feb. 27, 2017   Strategic ... fund, today announced it has led a $3.5 million investment ... collaboration platform. Strategic Cyber Ventures is DC based and ... and Hank Thomas . Ron Gula , ... Tech Ventures, also participated in this series A round ...
Breaking Biology News(10 mins):
(Date:3/28/2017)... ... March 28, 2017 , ... Benchworks ... 22 in Philadelphia. The event was offered by the Chamber of Commerce for ... featured breakout groups and interaction with speakers who are leaders in their industries. ...
(Date:3/28/2017)... , Belgium , March 28, 2017 ... VolitionRx Limited (NYSE MKT: VNRX), today announced the engagement of ... DVD Associates, LLC, as a strategic consultant. Dr. Vollmer ... identifying and securing non-dilutive funding in the State ... United States . Dr. Vollmer Dahlke has ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... initial release of LabKey’s newest software solution, LabKey Biologics . Built in ... pharma and biotech organizations, LabKey Biologics provides drug research teams tools for biological ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... development of a new orally administered treatment for Alzheimer’s disease (AD), today announced ... Didsbury states, “As we seek to uniquely treat the metabolic dysfunctions inherent in ...
Breaking Biology Technology: